• MitoCareX, a wholly owned Nexentis unit, added Bar-Ilan University chemistry professor Dan T. Major to its scientific advisory board.
• Appointment targets expanded in silico drug-discovery capacity, supporting program evaluation and prioritization across the pipeline.
• MitoCareX already uses computationally guided discovery, including an AI-driven collaboration with Boltz on biomolecular models and workflows.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nexentis Technologies Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609240750PRIMZONEFULLFEED9833321) on September 24, 2026, and is solely responsible for the information contained therein.